GO-BEYOND: A Real-World Study of Persistence of Golimumab in Patients with Axial Spondyloarthritis and Rheumatoid Arthritis in Turkey

Abstract

Aim: To evaluate the retention rate of golimumab (GLM) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (ax-SpA). Materials & methods: Patients had received/were receiving GLM as their first or second biological drug for at least 3 months. We recorded demographic and clinical data, data on drug continuation and disease activity. Patients were classified as biologic-naive and biologic-experienced. Results: The study included 60 RA and 269 ax-SpA patients. At month 24, the retention rates were 67.2 and 57.1% (biologic-naive and biologic-experienced RA) and 74.8 and 80.4% (anti-TNF-naive and -experienced ax-SpA). No significant differences in retention were observed between the biologic-naive and -experienced groups for either disease. Conclusion: The results of this study confirm the effectiveness of GLM in the treatment of RA and axSpA with good retention rates at 2 years in a real-world setting in Turkey.

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study

“…This real-life prospective study specifically focused on the effectiveness of GLM in a subgroup of patients who are not normally included in clinical trials, and our findings reveal that in patients with spondyloarthropathies (axSpA and PsA) as well as RA, who need to discontinue their first anti-TNF drug, the decision to switch to GLM can be considered a suitable therapeutic choice. These findings are in agreement with results reported in other recent real-life studies [ 21 , 22 , 23 , 24 , 25 , 26 ].…”

“…In our cohort, which shares similar clinical characteristics with the Spanish study in terms of disease duration, comorbidities and concomitant medication, we observed a similar reduction in DAS28-CRP by 3 months in PsA patients (3.8 ± 0.99 at baseline to 2.8 ± 1.1; p < 0.0001) as well as a decrease in BASDAI in axSpA patients (6.02 ± 2.09 at baseline to 4.9 ± 2.2; p < 0.001), although baseline disease activity was higher in our axSpA population. Patients with RA were not included in the study by Alegre-Sancho et al; however, a similar study (in terms of design and patient characteristics) undertaken in Turkey (GO-BEYOND Turkey) did include RA patients [ 22 ]. Akar et al evaluated persistence and changes in disease activity measures over 2 years in 60 RA and 269 axSpA patients after GLM treatment.…”

“…However, in patients with PsA or axSpA, data on the effectiveness of GLM following the first-line anti-TNF failure are scarce [ 19 , 20 ]. To address this gap, recent real-life retrospective studies performed in Spain [ 21 ], Turkey [ 22 ], France [ 23 , 24 ], Germany [ 25 ] and Italy [ 26 ] have examined the long-term effectiveness and retention rate of GLM. The present prospective study, GO-BEYOND, was designed to evaluate the effectiveness of GLM as a second anti-TNF drug in patients with RA, axSpA or PsA who discontinued a first anti-TNF drug.…”

Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study

“…QoL by EQ-5D-5L Domain (% patients with some problems) 1.18) and BASDAI (4.3 vs. 1.6). 9 The smaller improvement observed in the present study may be due to older age of axSpA patients (51 vs. 40 years) and higher CRP levels, and ASDAS and BASDAI scores at baseline. 9 Results from the Italian GISEA registry also corroborate with our findings.…”

“…9 The smaller improvement observed in the present study may be due to older age of axSpA patients (51 vs. 40 years) and higher CRP levels, and ASDAS and BASDAI scores at baseline. 9 Results from the Italian GISEA registry also corroborate with our findings. 13 A similar reduction in DAS28 (from 4.9 ± 1.2 at baseline to 3.1 ± 1.2 at 12 months) in the subgroup of RA patients who were inadequate responders to one biologic (N = 94) was observed.…”